MX2019002698A - Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb. - Google Patents
Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb.Info
- Publication number
- MX2019002698A MX2019002698A MX2019002698A MX2019002698A MX2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A MX 2019002698 A MX2019002698 A MX 2019002698A
- Authority
- MX
- Mexico
- Prior art keywords
- worsening
- progression
- mitigate
- prevent
- ameliorating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Las modalidades incluyen métodos para mitigar o prevenir el empeoramiento o progresión y/o mitigar o prevenir el empeoramiento o la ausencia de mejoría de los síntomas HPB en mamíferos, mediante el uso de composiciones que contienen compuestos basados en péptidos pequeños y un portador farmacéuticamente aceptable. El método incluye, pero no se limita a, la administración de los compuestos por vía intramuscular, por vía oral, por vía intravenosa, por vía intraprostatica, por vía intratecal, por vía intratumoral, por vía intranasal, por vía tópica, por vía transdermica, etc., ya sea solos o conjugados con un portador a un mamífero que lo necesite.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/258,786 US10532081B2 (en) | 2016-09-07 | 2016-09-07 | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| PCT/IB2017/055187 WO2018047036A1 (en) | 2016-09-07 | 2017-08-29 | Method of ameliorating or preventing the worsening or the progression of symptoms of bph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002698A true MX2019002698A (es) | 2020-07-22 |
Family
ID=59829424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002698A MX2019002698A (es) | 2016-09-07 | 2017-08-29 | Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10532081B2 (es) |
| EP (2) | EP4275688A3 (es) |
| JP (2) | JP2019531278A (es) |
| KR (1) | KR102623470B1 (es) |
| CN (1) | CN109890401A (es) |
| AU (1) | AU2017325033B2 (es) |
| BR (1) | BR112019004532A2 (es) |
| CA (1) | CA3036089A1 (es) |
| MX (1) | MX2019002698A (es) |
| NZ (1) | NZ751862A (es) |
| RU (1) | RU2744691C2 (es) |
| WO (1) | WO2018047036A1 (es) |
| ZA (1) | ZA201901449B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835538B2 (en) * | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| CN113543792A (zh) | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| US20200360466A1 (en) * | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11231421B2 (en) * | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423507A (en) | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3121153A1 (de) | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
| US4457489A (en) | 1981-07-13 | 1984-07-03 | Gilmore Samuel E | Subsea fluid conduit connections for remote controlled valves |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US4775660A (en) | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4659695A (en) | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
| US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| CA1310924C (en) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| ES2094733T3 (es) | 1988-12-21 | 1997-02-01 | Gen Hospital Corp | Deteccion de enfermedades o disfunciones neurologicas. |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| JPH06256387A (ja) | 1991-06-14 | 1994-09-13 | Suetsuna Yoko | 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤 |
| NZ266072A (en) | 1993-04-20 | 1997-07-27 | Gen Hospital Corp | Neural thread protein and its use in detecting alzheimers, neuroectodermal tumours, malignant astrocytomas and glioblastomas |
| ATE218893T1 (de) | 1993-08-12 | 2002-06-15 | Neurotech Sa | Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| ZA951877B (en) | 1994-03-07 | 1996-09-09 | Dow Chemical Co | Bioactive and/or targeted dendrimer conjugates |
| US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
| CA2222550A1 (en) | 1995-06-07 | 1996-12-19 | Baylor College Of Medicine | Nucleic acid transporters for delivery of nucleic acids into a cell |
| US6660830B1 (en) | 1996-03-26 | 2003-12-09 | Razvan T Radulescu | Peptides with antiproliferative properties |
| US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
| CA2282729A1 (en) | 1997-02-26 | 1998-09-03 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease |
| WO1999019347A1 (en) | 1997-10-10 | 1999-04-22 | Astrazeneca Ab | Synthetic genes with immunomodulatory effects |
| WO2000028004A1 (en) | 1998-11-10 | 2000-05-18 | The University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| EP1135494A2 (en) | 1998-12-11 | 2001-09-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| WO2000063230A2 (en) | 1999-03-26 | 2000-10-26 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| JP2002542766A (ja) | 1999-03-12 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ５０個のヒト分泌タンパク質 |
| AU3628600A (en) | 1999-03-19 | 2000-10-09 | Human Genome Sciences, Inc. | 46 human secreted proteins |
| AU3765500A (en) | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| CA2368927A1 (en) | 1999-03-26 | 2000-10-05 | Craig A. Rosen | 45 human secreted proteins |
| CN1300779A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸 |
| AU2001271455A1 (en) | 2000-06-26 | 2002-01-08 | Millennium Pharmaceuticals, Inc. | A human calcium channel protein and uses thereof |
| US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| CA2325666A1 (fr) | 2000-12-01 | 2002-06-01 | Institut Pasteur | Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques |
| US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| DE60222745T2 (de) | 2001-03-08 | 2008-07-10 | Nymox Pharmaceutical Corp., St. Laurent | Verwendung von neurofilamentproteinen zur behandlung von tumoren |
| KR20040008177A (ko) | 2001-05-16 | 2004-01-28 | 니목스 코포레이션 | 신경 사 단백질 세그먼트를 사용하여 세포 사멸을억제하는 방법 |
| DE60217326T2 (de) | 2001-05-25 | 2007-10-18 | Nymox Corp., Saint-Laurent | Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung |
| IL159903A0 (en) | 2001-07-19 | 2004-06-20 | Nymox Corp | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| WO2005113720A2 (en) | 2004-05-19 | 2005-12-01 | Auburn University | A strategy for designing patient-specific anti-cancer drugs |
| MX2008010942A (es) * | 2006-02-28 | 2008-09-03 | Nymox Corp | Peptidos efectivos en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas. |
| EA200801942A1 (ru) | 2006-03-10 | 2009-02-27 | Наймокс Корпорейшн | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон |
| US9243035B2 (en) | 2013-11-26 | 2016-01-26 | Nymox Corporation | Peptides effective in the treatment of conditions requiring the removal or destruction of cells |
| US20160215031A1 (en) | 2015-01-27 | 2016-07-28 | Nymox Pharnaceutical Corporation | Method of treating disorders requiring destruction or removal of cells |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
-
2016
- 2016-09-07 US US15/258,786 patent/US10532081B2/en not_active Expired - Fee Related
-
2017
- 2017-08-29 EP EP23193577.6A patent/EP4275688A3/en active Pending
- 2017-08-29 CN CN201780063432.9A patent/CN109890401A/zh active Pending
- 2017-08-29 NZ NZ751862A patent/NZ751862A/en unknown
- 2017-08-29 BR BR112019004532-5A patent/BR112019004532A2/pt unknown
- 2017-08-29 MX MX2019002698A patent/MX2019002698A/es unknown
- 2017-08-29 AU AU2017325033A patent/AU2017325033B2/en active Active
- 2017-08-29 WO PCT/IB2017/055187 patent/WO2018047036A1/en not_active Ceased
- 2017-08-29 JP JP2019512858A patent/JP2019531278A/ja active Pending
- 2017-08-29 EP EP17764662.7A patent/EP3509620A1/en not_active Withdrawn
- 2017-08-29 CA CA3036089A patent/CA3036089A1/en active Pending
- 2017-08-29 RU RU2019110137A patent/RU2744691C2/ru active
- 2017-08-29 KR KR1020197009879A patent/KR102623470B1/ko active Active
-
2019
- 2019-03-08 ZA ZA201901449A patent/ZA201901449B/en unknown
-
2022
- 2022-12-09 JP JP2022197208A patent/JP2023036673A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019110137A (ru) | 2020-10-08 |
| JP2019531278A (ja) | 2019-10-31 |
| WO2018047036A1 (en) | 2018-03-15 |
| RU2019110137A3 (es) | 2020-12-07 |
| EP3509620A1 (en) | 2019-07-17 |
| BR112019004532A2 (pt) | 2019-06-25 |
| CA3036089A1 (en) | 2018-03-15 |
| EP4275688A3 (en) | 2024-01-17 |
| ZA201901449B (en) | 2020-11-25 |
| NZ751862A (en) | 2025-11-28 |
| AU2017325033A1 (en) | 2019-04-11 |
| EP4275688A2 (en) | 2023-11-15 |
| US10532081B2 (en) | 2020-01-14 |
| CN109890401A (zh) | 2019-06-14 |
| AU2017325033B2 (en) | 2024-11-14 |
| KR20190050813A (ko) | 2019-05-13 |
| RU2744691C2 (ru) | 2021-03-15 |
| US20180064785A1 (en) | 2018-03-08 |
| KR102623470B1 (ko) | 2024-01-09 |
| JP2023036673A (ja) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002698A (es) | Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb. | |
| MX380201B (es) | Péptido de la cadena neural para prevenir o reducir el avance de cáncer de próstata. | |
| MX2017016106A (es) | Composiciones de combinacion para tratar trastornos que requieren de la remocion o destruccion de proliferaciones celulares no deseadas. | |
| MX391695B (es) | Péptido derivado de una proteína de hebra neural para uso en el tratamiento de desordenes que requieren la destrucción o retiro de células | |
| MX2023009631A (es) | Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi. | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| AU2016219611A1 (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| MX380399B (es) | Acoplador. | |
| BR112015029240A2 (pt) | composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo | |
| MX2015012783A (es) | Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13). | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| JOP20200004A1 (ar) | تركيبات طويلة المفعول | |
| AR109799A1 (es) | Composición para el tratamiento del cabello | |
| MX2022001133A (es) | Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido). | |
| AR110404A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES FIBRÓTICAS UTILIZANDO EL INTERFERÓN-l | |
| UY38969A (es) | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos | |
| MX2019010394A (es) | Composiciones y metodos para mejorar la funcion sexual. | |
| MX383944B (es) | Composiciones para el cuidado personal. | |
| BR112017007025A2 (pt) | sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio | |
| MX2020007760A (es) | Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano. | |
| AR095015A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| MX2020007162A (es) | Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina. | |
| MX2021012824A (es) | Métodos para tratar el prurito. |